Aethlon Medical, Inc. (AEMD)
Stock Price:
$2.03 USD
0.09 (4.64%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $1.97 -0.06 (-2.96%) Aug 3, 7:19 PM
Key Info
| Market Cap |
24.50M |
| Revenue (ttm) |
650,187 |
| Net Income (ttm) |
-6.37M |
| Shares Out |
12.07M |
| EPS (ttm) |
-1.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$2.03 |
| Previous Close |
$1.94 |
| Change ($) |
0.09 |
| Change (%) |
4.64% |
| Day's Open |
1.91 |
| Day's Range |
1.91 - 2.05 |
| Day's Volume |
247,008 |
| 52-Week Range |
0.76 - 6.89 |
More Stats
| Market Cap |
24.50M |
| Enterprise Value |
14.89M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
12.07M |
| Float |
11.79M |
| EPS (basic) |
-1.87 |
| EPS (diluted) |
-1.87 |
| FCF / Share |
-1.57 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
715,684 |
| Short Ratio |
0.10 |
| Short % of Float |
5.29% |
| Beta |
0.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
37.69 |
| PB Ratio |
2.51 |
| Revenue |
650,187 |
| Operating Income |
-5.93M |
| Net Income |
-6.37M |
| Free Cash Flow |
-5.35M |
| Net Cash |
9.62M |
| Net Cash / Share |
0.80 |
| Gross Margin |
100.00% |
| Operating Margin |
-912.04% |
| Profit Margin |
-980.30% |
| FCF Margin |
-822.73% |
| ROA |
-51.08% |
| ROE |
-110.22% |
| ROIC |
1,330.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
45.0
Current: $2.03
High
45.0
Target: 45.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.65 | 0.23 | 0.15 | 0.39 | 0.89 | 0.76 | 1.62 | 1.23 | 1.36 | - |
| Revenue Growth | 183.15% | 53.47% | -61.84% | -55.78% | 16.28% | -53.05% | 32.01% | -9.53% | - | - |
| Gross Profit | 0.65 | 0.23 | 0.15 | 0.39 | 0.89 | 0.76 | 1.62 | 1.23 | 1.36 | - |
| Operating Income | -5.93 | -6.00 | -4.83 | -6.10 | -4.38 | -3.99 | -3.06 | -3.58 | -3.11 | -4.56 |
| Net Income | -6.37 | -6.19 | -5.68 | -7.28 | -4.87 | -6.80 | -13.36 | -4.89 | -8.11 | -5.71 |
| Shares Outstanding | 3.41 | 1.21 | 0.82 | 0.52 | 0.49 | 0.37 | 0.26 | 0.20 | 0.14 | 0.09 |
| Earnings Per Share | -1.87 | -5.13 | -6.90 | -14.10 | -9.90 | -18.30 | -51.60 | -22.50 | -60.00 | -60.00 |
| Operating Cash Flow | -5.20 | -4.29 | -3.91 | -3.51 | -4.33 | -5.05 | -2.14 | -2.10 | -1.84 | -1.97 |
| Capital Expenditures | -0.15 | - | -0.02 | -0.02 | -0.01 | - | -0.10 | - | - | - |
| Free Cash Flow | -5.35 | -4.29 | -3.94 | -3.52 | -4.34 | -5.05 | -2.24 | -2.10 | -1.84 | -1.97 |
| Cash & Equivalents | 9.62 | 3.84 | 6.99 | 1.57 | 2.15 | 0.86 | 1.25 | 0.13 | 0.15 | 0.22 |
| Total Debt | - | 0.96 | 0.84 | 0.52 | 0.50 | 0.16 | 2.53 | 2.69 | 3.66 | 2.37 |
| Net Cash / Debt | 9.62 | 2.88 | 6.15 | 1.06 | 1.65 | 0.70 | -1.28 | -2.56 | -3.51 | -2.15 |
| Assets | 10.39 | 4.12 | 7.35 | 1.73 | 2.53 | 1.38 | 1.70 | 0.50 | 0.84 | 0.57 |
| Liabilities | 1.11 | 1.82 | 1.32 | 1.13 | 1.03 | 0.73 | 16.43 | 9.64 | 10.13 | 6.54 |
| Book Value | 9.41 | 2.43 | 6.13 | 0.68 | 1.55 | 0.62 | -14.95 | -9.14 | -9.30 | -5.98 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aethlon Medical, Inc. |
| Country |
United States |
| Employees |
8 |
| CEO |
Timothy C. Rodell |
Stock Information
| Ticker Symbol |
AEMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: AEMD |
Description
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. The company is based in San Diego, California.